Illumina (ILMN) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is ILMN's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Illumina, Inc. (ILMN) Presents at Jefferies Global Healthcare Conference 2026 Transcript…

Illumina NASDAQ: ILMN is seeing strong demand for its sequencing instruments from clinical customers, while remaining cautious about a recovery in research spending, Chief Financial Officer Ankur Dhingra said at a compan…

Thrivent Mid Cap Stock Fund returned (2.92%) versus the Russell Mid Cap Index's (3.00%) return. Top contributors include Veeva Systems, Illumina and Zebra Tech. Top detractors include RH and UL Solutions.…

Illumina NASDAQ: ILMN expects clinical demand and sequencing consumables to remain central to its growth strategy, even as research customers continue to face uncertainty over grant funding, executives said at a UBS disc…

Illumina, Inc. (ILMN) Presents at 2026 UBS Global Healthcare Conference Transcript…

Early access program launches to support ultrasensitive research into molecular residual disease and tumor evolution. New chemistry is optimized for highest possible accuracy, with reproducible detection of ctDNA at 2.5 …

Illumina, Inc. (NASDAQ: ILMN - Get Free Report) Director Keith Meister sold 50,000 shares of the business's stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $227.17, for a…

AIA Group Ltd trimmed its position in Illumina, Inc. (NASDAQ: ILMN) by 35.9% in a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,895 s…

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity…

SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore's healthcare system SINGAPORE, Nov. 2, 20…

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.…

Explore Illumina's (ILMN) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.…

Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.…

Illumina raises its 2026 guidance as strong clinical sequencing demand and NovaSeq X adoption fuel growth despite research weakness and pricing pressures.…

Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and t…

Illumina, Inc. (ILMN) Q3 2026 Earnings Call Transcript…

Illumina (ILMN) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.34 per share a year ago.…

Illumina NASDAQ: ILMN reported third-quarter results above its prior guidance, citing strong clinical sequencing demand, elevated NovaSeq X instrument placements and disciplined spending. The company raised its full-year…

Illumina (NASDAQ:ILMN) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.…

SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2026. Third quarter 2026 results Reported re…

The Fund declined 4.75% while the Russell 2500 Index declined 6.37%. Key contributors include Illumina, Revvity and Waystar. Key detractors include Regal Rexnord, Knife River and Red Rock Resorts.…

Evaluate the expected performance of Illumina (ILMN) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insigh…

SAN DIEGO, Oct. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference Jefferies Glo…

DRAGEN Ultra, BioInsight Platform Workflow Orchestrator, and BioInsight Platform Learning Cohorts are now available in early access, incorporating new AI-driven approaches to analysis, automation, and discovery The tools…

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference UBS Global He…

The new platform brings together advanced analysis, purpose-built AI, and curated biological data so researchers can move more quickly from complex genomic and multiomic data to actionable insight Included in the new pla…

SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2026 following the close of market on Thursday, October 29, 2026. On the same day, at…

In a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing models Illumina's genomic AI models now collectively enable researchers to identify 2x as many varian…

NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, Septem…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 8. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

